◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral PRIMARY-PICK HIGH

Modafinil

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict PRIMARY-PICK HIGH

Best-evidenced eugeroic with 25+ years of safety data, low tolerance, low abuse liability, cheap gray-market sourcing. Confidence would only drop if Dylan develops rash (SJS), persistent insomnia, or unmanageable anxiety in first 8 weeks.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    PRIMARY PICK

    Best-evidenced eugeroic for sustained 6-12 hour cognitive output without amphetamine brain-development concerns. 100mg AM, 5-6×/week. Brain-dev risk is real (PFC matures into late 20s) but lower than any classical stimulant alternative because modafinil doesn't force monoamine release and shows no neurotoxicity. The orexin/histamine pathway is the cleanest mechanism for 20yo cognitive enhancement currently on the market. Caveat: stay vigilant for SJS in first 8 weeks; monitor sleep quality with concrete tracking.

  • 30-50, executive maintenance
    PRIMARY PICK

    Same evidence base, slightly less brain-dev concern. Common executive use case. 100-200mg AM. Watch hormonal contraceptive interaction if partner-relevant. Common stack: + caffeine 200mg + L-theanine 200mg morning routine.

  • 50+, mild cognitive decline
    STRONG CANDIDATE

    Some evidence of benefit in mild cognitive impairment and post-stroke fatigue, but cardiovascular contraindications matter more (HTN, LVH common in this group). 100mg AM with BP monitoring. Donepezil/rivastigmine may have stronger disease-specific rationale; modafinil is more about *current-day* cognitive function than slowing decline.

  • Anxiety-prone
    OPTIONAL ADD

    ~10-15% of anxiety-prone users find modafinil intolerable. Start at 50mg. Mandatory L-theanine 200mg co-administration. If panic-prone history, try selegiline or bromantane first; modafinil third-line.

  • High athletic load, tested status
    SKIP

    if WADA-tested (banned in-competition since 2004). Out-of-competition use detectable for ~2-4 days post-dose. PRIMARY PICK if untested (Dylan): real endurance support (Jacobs 2004 data), cognitive support during heavy training cycles, no testosterone/HPG impact. Caveat: HR rises 5-10 bpm submax which can corrupt heart-rate-zone training data.

  • DylanCombat-athlete (MMA / BJJ / boxing / Muay Thai, untested division — Dylan's profile)
    PRIMARY PICK

    Modafinil's profile aligns unusually well with combat-sport demands: (a) sustained vigilance + reaction-time preservation across 6-12 hour training/recovery/cognitive-work blocks; (b) reduced fatigue without amphetamine-class sympathetic load that would amplify pre-competition adrenaline; (c) no testosterone/HPG impact; (d) no significant lean-mass or appetite suppression at 100 mg (vs. amphetamine-class options that disrupt fueling for 10+ hr/wk training); (e) tolerance is low so dosing the morning of a hard sparring day or competition prep is sustainable; (f) cleaner discontinuation than amphetamines if a fight requires WADA-style testing (although Dylan's amateur/untested status keeps this irrelevant). Specific combat-athlete cautions: (1) Subconcussive-impact + glutamatergic concern — modafinil mildly increases cortical glutamate; the post-impact glutamate environment with modafinil-on-board is mechanistically uncharacterized, so maintain robust antioxidant + NAC stack as hedge (Dylan: V4-locked); (2) HR elevation 5-10 bpm corrupts heart-rate-zone cardio training data — track perceived exertion or use power-based metrics for conditioning sessions on dose days; (3) avoid same-day dosing on hard sparring days until tolerance is established (subjective stimulation could read as anxiety pre-spar); (4) never dose on weight-cut days approaching competition if appetite suppression at higher doses (200 mg) is a factor for fueling; (5) pre-competition trial — never use modafinil for the first time on fight day; require ≥8 weeks of weekday-only experience before treating it as competition-day cognitive support. For Dylan specifically: 100 mg AM, 5-6×/week with weekend washout (skip Saturday before BJJ sparring + one rest day) is the established protocol — see §Dosing protocols for full rationale. PRIMARY PICK with a clean dosing-discipline framework.

  • Sleep-disordered
    PRIMARY

    PICK for excessive daytime sleepiness in narcolepsy, OSA-residual-EDS, SWSD. This is the FDA approval base. Won't fix the underlying disorder (CPAP/sleep hygiene/etc. still needed), but compensates well. Pitolisant or solriamfetol may be alternatives; armodafinil if smoother day-long curve preferred.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL ADD

    Useful for post-concussion fatigue (some open-label data), post-COVID brain fog, post-chemo cognitive impairment. Start low (50mg). Avoid in acute injury phase if HR/BP elevation is undesirable. Better recovery picks: Cerebrolysin, BPC-157, sleep optimization first.

  • Strength/anabolic-focused
    OPTIONAL ADD

    Mild appetite suppression at 100mg+ can interfere with bulking phase calorie targets. No anabolic effect. Useful for cognitive focus during high-volume training or to push through training fatigue, but not central to a strength-anabolic stack. In a cutting/recomp phase, the appetite reduction can be a feature, not a bug.

▸ Subjective experience (deep)

Onset: 30-90 minutes. Tmax 1.5-2.5 hr (food delays absorption ~30-60 min, doesn't change AUC).

Peak: 2-4 hours after dose. Effect feels like "best night of sleep of your life" rather than caffeine's edge or amphetamine's push. No euphoria. No "high." Just absence of fatigue + intact motivation.

Plateau: 6-10 hours of clear cognitive runway at 100-200mg. No peak-and-crash like amphetamines.

Taper: Gradual fade over hours 8-14. Some users report a "still slightly on" feeling at hour 12 — partly because R-modafinil (the long-half-life enantiomer) has cleared only ~50% by then.

Characteristic effects:

  • Reduced drowsiness/yawning that's startling on first dose (especially for someone with zero stimulant baseline like Dylan)
  • Increased motivation to start tasks (the dopamine + D1 effect)
  • Sustained attention without the "tunnel" of amphetamines — easier to switch tasks than on Adderall, harder than baseline
  • Mild reduction in social patience / chattiness — some users report being more "focused" and less interested in small talk
  • Reduced appetite at higher doses (200mg+); minimal at 100mg
  • Mild increase in resting HR (~5-10 bpm) and BP (~3-5 mmHg systolic)
  • Some users get a faint "warm/dry eyes" feeling, urge to drink water (modafinil mildly suppresses thirst initially)

Honest variability: ~10-15% of users get more anxiety than benefit and don't tolerate it well. ~5% get nothing useful. Genetics (CYP3A4/CYP2C19 phenotype, COMT, DAT1) probably explain some of this.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal in clinical practice. 40-week open-label narcolepsy data shows no dose escalation. Mechanism makes sense — modafinil isn't depleting catecholamines, it's mostly enabling existing wake systems.
  • Anecdotal tolerance reports: Common online but poorly controlled. Likely sources: (1) sleep-debt creep — using modafinil to paper over progressively worse sleep, eventually outruns the drug; (2) tolerance to novelty (the first dose feels magical, the 50th feels like baseline-plus); (3) genuine pharmacodynamic tolerance in a subset of users — recent 2023 work (Cesta et al., Sleep Medicine) found pitolisant-bridged drug holidays could reduce required modafinil dose by 41%.
  • Recommended cycle: 5-6 days on, 1-2 days off per week. No need for monthly washouts unless tolerance signs appear. The weekly rest day reset is more about sleep recovery and "remembering what baseline feels like" than receptor recovery.
  • Reset protocol if needed: 1-2 weeks off, then resume at 100mg. If tolerance returns rapidly, the issue is likely upstream (sleep, stress, sleep debt) — fix that first.
▸ Stacking deep dive

Synergistic with

  • l-theanine (200mg co-administered): Single best stack. Smooths anxiety, reduces tension headache, doesn't blunt cognition. Already in Dylan's V4.
  • caffeine (post-modafinil onboarding only): Once Dylan has caffeine baseline established, ~100-200mg caffeine + 100mg modafinil layers nicely. Not on day 1.
  • bromantane (planned V5 add at week 4-6): Different mechanism (DAT/SERT modulation + tyrosine hydroxylase upregulation), no overlap, plausibly synergistic for sustained motivation.
  • citicoline (already V4, 500mg): Cholinergic support helps sustain modafinil's pro-cognitive effect on long workdays. Dylan covered.
  • rhodiola (already V4, 250mg): Anxiolytic adaptogen, smooths the adrenergic edge.
  • selegiline (planned V5 optional, 1-2.5mg): MAO-B selective inhibition preserves dopamine; pairs well with modafinil's DAT effect. Caution: above 10mg/day selegiline loses MAO-B selectivity.
  • alpha-gpc (Dylan's PRN): Acute cholinergic boost for high-load days. Don't stack daily — modafinil + Alpha-GPC + already-V4 citicoline is too much choline.

Avoid stacking with

  • MAO inhibitors (non-selective): Tranylcypromine, phenelzine, etc. — risk of hypertensive crisis. Selegiline at low MAO-B-selective doses (1-2.5mg) is fine.
  • Other strong DAT/NET stimulants daily (amphetamines, high-dose methylphenidate): Cumulative cardiovascular load, no additional cognitive benefit.
  • Yohimbine, high-dose synephrine: Stacked alpha-1/alpha-2 effects = anxiety + BP spike.
  • Other CYP3A4 inducers daily (rifampin, St. John's Wort, carbamazepine): Compound the contraceptive/opioid efficacy reduction.
  • Hormonal contraceptives (relevant for partners, not Dylan): See Drug Interactions.
  • Phenibut, GABAergic depressants near peak: Defeats the purpose. Fine in evening if mod cleared by then.

Neutral / safe co-administration

  • All Dylan's V4 supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no interactions known.
  • Creatine — neutral.
  • Standard SSRI/SNRI — neutral but watch for serotonin levels (modafinil isn't serotonergic enough to cause SS but the indirect 5-HT bump is real).
  • Most peptides Dylan is using/planning (Semax, Selank, Adamax, BPC-157, TB-500) — neutral.
▸ Drug interactions deep dive

Modafinil's metabolic profile:

  • Substrate of CYP3A4/3A5 (sulfoxidation pathway, ~10-15% of metabolism)
  • Major non-CYP metabolism via amide hydrolysis by esterases/amidases (~50%) — produces inactive modafinil acid
  • Aromatic hydroxylation + glucuronidation (~remainder)
  • Modafinil itself induces CYP3A4 (moderate) and CYP1A2 (weak); inhibits CYP2C19 (weak)
  • Inhibits CYP2D6 modestly via CYP2C19 cross-effect in poor metabolizers

Clinically significant interactions:

1. Hormonal contraceptives — REDUCED EFFICACY

  • 200-400mg/day modafinil reduced ethinyl estradiol AUC by 18% and Cmax by 11%. Levonorgestrel reduced by 18-32%. The pill, patch, ring, progestogen-only pill, implants, and ulipristal emergency contraception are all compromised during use and for 1 month after discontinuation.
  • Reliable alternatives during modafinil use: copper IUD, levonorgestrel-IUS (Mirena), depot progestogen injection (Depo-Provera).
  • Relevance for Dylan: Indirect — partner-relevant. If partnered with someone on hormonal contraception, additional barrier method or non-hormonal IUD is mandatory during his modafinil use.

2. Opioids — possibly reduced analgesia

  • CYP3A4 induction can reduce levels of methadone, hydrocodone, oxycodone, fentanyl. Relevant if Dylan ever needs post-injury opioids (e.g., MMA injury, surgery).

3. CYP2C19 substrates — possibly increased levels

  • Phenytoin, diazepam, omeprazole, propranolol (mild). Watch if any of these are co-prescribed.

4. CYP3A4 substrates — possibly reduced levels

  • Cyclosporine, certain statins, some calcium channel blockers, midazolam, triazolam.

5. Triazolam — large reduction

  • Modafinil reduced midazolam AUC ~32%. Same family.

6. SSRIs / TCAs in CYP2D6 PMs

  • Modafinil's mild CYP2C19 inhibition can raise tricyclic and SSRI levels in CYP2D6 poor metabolizers (since 2D6 PMs already rely on 2C19 as ancillary route). Relevant if Dylan ever goes on antidepressants and is a CYP2D6 PM (await 23andMe).

7. Warfarin — monitor INR

  • Mild interaction. Not relevant for Dylan absent thrombotic history.

8. Alcohol — minimal direct interaction but practically: modafinil-on-alcohol masks intoxication subjectively without changing BAC. Risk of overconsumption. (Dylan: zero alcohol baseline, non-issue.)

▸ Pharmacogenomics

CYP3A4 / CYP3A5 polymorphism: ~10% of caucasians have CYP3A5 expressers (rs776746), generally faster metabolizers. Effect on modafinil exposure is real but small (modafinil's main route is amide hydrolysis, not CYP).

CYP2D6 poor metabolizers: ~7-10% of Caucasians (Dylan's ethnicity). Modafinil itself is not primarily a 2D6 substrate, so PM status doesn't dramatically affect modafinil exposure. However: modafinil's mild CYP2C19 inhibition matters more in 2D6 PMs because they already lean on 2C19 for backup metabolism of other drugs (TCAs, SSRIs, codeine activation). Practical implication: if Dylan turns out to be a 2D6 PM and ever takes a TCA or codeine, modafinil amplifies exposure unpredictably. Wait for 23andMe results in June — interpret CYP2D6 status before any psychiatric/opioid co-prescription.

CYP2C19: Polymorphism here directly affects modafinil S-enantiomer clearance. *2 and *17 alleles common in caucasians. PMs have ~20-30% higher modafinil exposure on standard dose. If post-23andMe Dylan turns out to be a 2C19 PM, 50mg may be functionally equivalent to typical 100mg — dose down accordingly.

COMT Val/Val vs Val/Met vs Met/Met: Val/Val (faster dopamine clearance, "warriors") tend to respond more robustly to dopaminergic enhancers like modafinil. Met/Met may be more sensitive to anxiety side effects. Dylan's COMT status will be inferable from 23andMe raw data via Promethease — useful tuning data, not a blocker.

HLA-B alleles + SJS risk: SJS in carbamazepine and allopurinol is famously linked to HLA-B15:02 (Asian) and HLA-B58:01. Modafinil-SJS link to specific HLA alleles is not well established as of 2026 — case reports too sparse for reliable association. If Dylan has any first-degree family history of severe drug reactions, take 23andMe HLA data more seriously.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Indian online pharmacy (gray market) ModafinilXL $0.50-1.50/pill (200mg Modalert), bulk discount; 20% crypto discount High (10+ year operator, 15k+ Yotpo reviews, WHO-GMP source from Sun Pharma + HAB Pharma + Centurion + HOF) Shipping 12-18 days to US (slowed late 2024). Reship guarantee on customs seizures. Legal note: importing Schedule IV without Rx is technically illegal but routinely tolerated for personal-use quantities; FDA and DEA do not prosecute small individual orders.
Indian online pharmacy BuyModafinilOnline (BMO) Same range High (sister to ModafinilXL) Backup vendor. Same brands.
Indian online pharmacy ModaMike Similar Medium (newly launched 2025 by ex-BuyModa owner; track record being established) BuyModa shut down May 2025; old buymoda.su domain compromised — do not use.
US Rx telehealth Hello Klarity, GoodRx-affiliated, Premier Hormone $20-60/mo with insurance; $30-120/mo cash High legality Requires legitimate diagnosis: narcolepsy (rare), shift work sleep disorder (achievable for night-owl chronotype), OSA with residual sleepiness (requires sleep study). Synchronous video required for Schedule IV in most states.
US local pharmacy Generic via prescription $20/mo GoodRx; $300/mo brand Provigil High Cleanest path if Rx is obtained.
Compounding pharmacy Various Variable Medium For non-standard doses (e.g., 50mg pure tablets). Mostly unnecessary — pill-cut a 200mg tablet.

Brand-by-brand quality (Indian generics, all WHO-GMP):

  • Modalert (Sun Pharma, 200mg) — gold standard. Most consistent batch quality. ~$0.80-1.20/pill.
  • Modvigil (HAB Pharma, 200mg) — slightly cheaper, slightly less peak by anecdote. $0.50-0.80/pill.
  • ModaXL (HOF Pharma, 200mg) — newer premium brand, claims ~30% greater peak intensity. ~$1.00-1.50/pill. Marketing skepticism warranted but quality reports are consistent.
  • Artvigil/Waklert — these are armodafinil brands; see armodafinil.md.
  • Modafil MD (Sun Pharma, sublingual, 100mg) — fast-onset oral disintegrating tablet. Useful for shift workers; faster Tmax. Less commonly stocked.

For Dylan: order Modalert 200mg in bulk (e.g., 100 pills × $0.80 = $80 for ~5 month supply at 50% pill-split daily use), with optional 30× Artvigil 150mg for the planned A/B comparison at week 8-12 per V5 plan.

Payment: Crypto (BTC/ETH) gets 20-25% discount and avoids credit card chargebacks if customs intercepts. Traditional cards work but issuers occasionally flag international pharma transactions.

Shipping: Use a reliable address. Boxes are typically declared as generic supplements. Customs interception rate for individual orders <100 pills is low (~5-10%) but vendors will reship at no charge.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Resting HR + BP (arm cuff, 3-day morning average) — modafinil typically adds 5-10 bpm and 3-5 mmHg
  • ALT/AST (liver) — covered in June 2026 bloodwork panel; modafinil has minimal hepatic toxicity but baseline matters
  • TSH, fT4 — modafinil can mask hypothyroid fatigue symptoms; don't want to miss a treatable condition
  • Subjective sleep quality VAS (Karolinska Sleepiness Scale or simple 1-10) for 7 days pre-dose
  • Anxiety baseline (GAD-7 or simple 1-10 daily VAS)
  • Skin photographic baseline (front torso, back, arms) — useful comparator if any rash develops in week 1-8
  • 25(OH)D and ferritin — fatigue causes; don't want modafinil to paper over a deficiency

During use

  • Weeks 1-8: daily skin check — any new rash → stop drug, photograph, see PCP/derm same-day if mucosal involvement, fever, or peeling.
  • Weeks 1-2: daily headache, anxiety, sleep onset time tracking — if any persists or worsens, drop dose to 50mg.
  • Weekly: subjective cognitive performance VAS, mood, motivation — compare on-days vs off-days.
  • Monthly: morning HR + BP (simple home measurement).
  • 3 months: liver panel + CBC if planning long-term use.
  • 6 months: full repeat bloodwork — ALT/AST, lipids, fasting glucose, HbA1c, TSH, CRP. Modafinil shouldn't move any of these meaningfully but verify.

Post-cycle (if cycled)

  • Sleep architecture restoration check (Oura ring or subjective): expect REM/deep to rebound within 1-2 nights off.
  • Subjective baseline cognition check: after a full week off, do you feel notably worse than during use? This calibrates real benefit vs placebo/expectancy effect.
▸ Controversies / open debates Live debate

1. "Tolerance — real or anecdotal?"

  • Clinical view: No measurable tolerance in narcolepsy patients across 40+ weeks. Receptor mechanism doesn't predict tolerance.
  • Forum view: "First few weeks were magic, now it just feels normal" — extremely common report.
  • Probable reconciliation: What users call tolerance is mostly (a) regression of the novelty/expectancy effect, (b) sleep-debt creep masked by the drug, (c) genuine pharmacodynamic tolerance in a CYP/genetic subset. The 2023 Cesta et al. work using pitolisant-bridged drug holidays validated that some users do develop genuine tolerance and benefit from breaks.

2. "Cognitive enhancement in healthy adults — meaningful or marginal?"

  • Battleday/Brem (2015): Yes, on complex tasks.
  • Roberts (2020): Yes but small (g~0.10-0.28).
  • Practical view: Effect size matters less than user-experience reliability — modafinil consistently makes the day feel productive even if standardized cognitive batteries show modest changes. The disconnect is partly because lab tasks are short and ceiling-bound, while real-world cognitive output runs for 6-12 hours where fatigue resistance dominates.

3. "Brain development concern at age 20 — overstated?"

  • Conservative view: PFC develops into mid-late 20s; chronic dopaminergic stimulation could theoretically disrupt synaptic pruning and dopaminergic axon growth. Extrapolation from amphetamine and methylphenidate animal data.
  • Modafinil-specific data: Limited. One preadolescent rat study (Loureiro et al. 2022) showed altered VTA GABA, PFC D2 expression, and non-selective attention impairment — but at high relative doses and in still-developing brains very different from a 20yo.
  • Practical view: Modafinil's brain-dev risk is lower than any classical stimulant and probably lower than chronic high-dose caffeine, but it's not zero. The 5-6× per week dosing with weekend rest is partly a hedge against this. Reassess at age 25-26 when PFC is closer to mature.

4. "Microdose efficacy — real or placebo?"

  • No clinical trial data below 100mg.
  • Wide anecdotal support for 50mg daily-use protocol with reduced side effects.
  • Probable answer: real but reduced. 50mg is roughly 25-30% DAT occupancy (extrapolating from 200mg=50% data) — enough to feel something but milder.

5. "Indian generics vs brand Provigil — equivalent?"

  • Sun Pharma's Modalert is WHO-GMP and bioequivalence studies have shown comparable PK to Provigil. Real-world reports support equivalence.
  • Cheaper-tier generics (some Modvigil batches in 2018-2020) had reported potency variance. Sun Pharma is the safest choice.

6. "Is modafinil a 'classical stimulant' after all?"

  • The DAT occupancy data (Volkow 2009) was a shock — modafinil's striatal DA effects look stimulant-like at the receptor level, even though subjective and behavioral profiles differ. Recent papers (Mereu et al. 2017, Vázquez et al. 2025) reframe modafinil as an "atypical CNS stimulant" rather than the cleaner "non-stimulant" it was originally marketed as. Implication: the abuse-liability and dependence ceiling may be slightly higher than the 1990s marketing suggested. Still vastly lower than amphetamines.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: PRIMARY-PICK / HIGH CONFIDENCE. Best-evidenced eugeroic; locked into V5 plan at 100mg AM, 5-6×/week. Confirms encyclopedia entry from 2026-05-05.
  • (No prior verdicts in compound-file format; encyclopedia entry was already PRIMARY WAKEFULNESS PICK.)
▸ Open questions / gaps Open
  1. CYP2D6 / CYP2C19 status awaiting 23andMe results (June 2026). Will calibrate dose response.
  2. HLA-B SJS susceptibility — no validated marker yet for modafinil-SJS specifically. Watch literature 2026-2027 for HLA-B associations.
  3. Long-term cognitive trajectory in healthy 20yo daily users — no good prospective data exists. Dylan's use will be n=1 evidence.
  4. R-modafinil vs racemic for late-chronotype — should resolve via the planned week-8-12 A/B comparison with Artvigil (armodafinil) 150mg.
  5. Tolerance signature in non-narcolepsy users — the 2023 pitolisant-bridge data is suggestive but not definitive. Worth re-checking at month 6.
  6. MMA-specific cognitive protection trade-off — modafinil increases glutamatergic excitatory transmission. In a sport with subconcussive impact (Dylan's daily light sparring), is the post-impact glutamate environment with modafinil-on-board a meaningful risk? No data exists on this. Worth keeping antioxidant + N-acetylcysteine stack robust as hedge (already V4-locked).
  7. Sleep architecture cost vs cognitive gain — quantify with Oura/sleep ring once Dylan starts. Acceptable threshold needs deciding upfront (e.g., "if deep+REM drops >10% on dose days, reduce dose").
▸ Sources (full, with our context)
Back to compact view